Jubilant Pharmova Executive and Leadership Team

Harsher Singh, the Chief Executive Officer - Jubilant Radiopharma at Jubilant Pharmova, directs the strategic expansion of nuclear medicine and diagnostic imaging portfolios. Singh oversees the development of specialized radiopharmaceutical products designed to improve patient outcomes in oncology and cardiology. By managing complex supply chains across North American and European markets, the Chief Executive Officer - Jubilant Radiopharma ensures consistent delivery of time-sensitive medical isotopes. This leadership role involves close collaboration with regulatory bodies to maintain compliance and safety standards. Harsher Singh drives innovation within the radiopharma division by prioritizing research into targeted molecular therapies. Through the optimization of manufacturing processes, the division achieves greater operational efficiency and market penetration. Ultimately, Singh secures the competitive position of the company within the global diagnostic sector by fostering partnerships with major healthcare providers and research institutions.

Robert Ferguson, the Chief Executive Officer, Allergy Business at Jubilant Pharmova, manages the comprehensive portfolio of allergy immunotherapy and diagnostic products. Ferguson directs the commercial strategy for the allergy business unit, focusing on expanding market reach across diverse international territories. The Chief Executive Officer, Allergy Business coordinates with clinical research teams to advance the development of novel treatments for respiratory and immunological conditions. By analyzing market trends and patient needs, Ferguson identifies growth opportunities that align with the broader biopharmaceutical mission. This role requires constant engagement with medical professionals to ensure the effective adoption of allergy-focused therapies. Robert Ferguson drives revenue growth by streamlining distribution channels and enhancing product accessibility. Through the implementation of targeted marketing initiatives, the allergy business unit maintains a strong presence in the competitive pharmaceutical landscape, ultimately improving the quality of life for patients suffering from chronic allergic conditions.

Ashish Mukkirwar, the President & Chief Financial Officer at Jubilant Pharmova, directs the financial strategy, capital allocation, and investor relations for the organization. Mukkirwar oversees the budgeting process and financial reporting to ensure transparency and fiscal health. By managing the company's balance sheet and investment portfolio, the President & Chief Financial Officer supports the funding of research and development projects. This leadership role involves analyzing market risks and opportunities to guide long-term financial planning. Ashish Mukkirwar coordinates with the board of directors to communicate financial performance and strategic direction to stakeholders. Through the implementation of robust financial controls, the President & Chief Financial Officer ensures compliance with international accounting standards. By optimizing the capital structure, Mukkirwar drives sustainable growth and shareholder value. This focus on financial discipline enables the company to invest in cutting-edge biopharmaceutical technologies while maintaining a strong competitive position in the global market.

Arul Ramakrishnan, the Chief Operating Officer at Jubilant Pharmova, directs the internal operational infrastructure and manufacturing excellence across all business units. Ramakrishnan oversees the integration of advanced production technologies to ensure high-quality output in pharmaceutical manufacturing. By managing cross-functional teams, the Chief Operating Officer drives efficiency in supply chain logistics and resource allocation. This leadership role involves implementing lean manufacturing principles to reduce waste and optimize production timelines. Arul Ramakrishnan coordinates with the executive board to align operational capabilities with long-term corporate objectives. Through the oversight of facility management and quality control protocols, the Chief Operating Officer ensures adherence to global regulatory standards. By fostering a culture of continuous improvement, Ramakrishnan enhances the overall productivity of the organization. This strategic focus on operational excellence supports the company's ability to scale production capacity while maintaining the highest levels of product integrity and safety.

Ward Barney, the Chief Operating Officer Cadista at Jubilant Pharmova, directs the manufacturing and distribution operations specifically for the Cadista generic pharmaceutical division. Barney oversees the production of high-volume generic medications, ensuring cost-effective and timely delivery to retail and wholesale markets. By managing the technical operations and facility maintenance at the Cadista site, the Chief Operating Officer Cadista maintains strict adherence to Good Manufacturing Practices. This leadership role involves optimizing production workflows to maximize output and minimize downtime. Ward Barney coordinates with the supply chain team to ensure the availability of raw materials and the efficient distribution of finished goods. Through the implementation of quality assurance programs, the Chief Operating Officer Cadista guarantees the safety and efficacy of all generic products. By focusing on operational agility, Barney supports the company's goal of providing affordable healthcare solutions to a broad patient base across diverse geographic regions.

Shantanu Jha, the Group Chief Human Resources Officer at Jubilant Pharmova, directs the global talent strategy and organizational development initiatives. Jha oversees the recruitment, retention, and professional growth of the workforce to support the company's biopharmaceutical mission. By designing comprehensive compensation and benefits programs, the Group Chief Human Resources Officer ensures the attraction of top-tier scientific and operational talent. This leadership role involves fostering an inclusive corporate culture that promotes innovation and collaboration across international offices. Shantanu Jha drives performance management systems that align individual contributions with the strategic goals of the organization. Through the implementation of leadership development programs, the Group Chief Human Resources Officer prepares the next generation of managers to navigate the complexities of the pharmaceutical industry. By prioritizing employee engagement and wellness, Jha maintains a high-performing workforce capable of meeting the evolving demands of the global healthcare market.